Triglyceride Lowering Study

Status Recruiting

Clinical Trial Summary

Lovaza is a special fish oil concentrate, that prescribed at 4 g a day to reduce certain fat (triglycerides) levels in blood.Our goal is to study how Lovaza at doses of 4, 8, and 12 grams per day will reduce fats in the blood of the patients with very high level of triglycerides. Our hypothesis is that patients with very high triglycerides will respond more with higher doses of Lovaza (8 g per day and then 12 g per day).

Clinical Trial Description

Lovaza contains Omega-3 fatty acids, the family of poly- unsaturated fatty acids. Omega-3 fatty acids stimulate blood circulation, increases the breakdown of fibrin, and additionally has been shown to reduce blood pressure, cardiac events and mortality from congestive heart failure. There is strong scientific evidence that omega 3 fatty acids significantly reduce blood triglyceride levels while elevating high density lipoprotein cholesterol (HDL) levels. Fasting and non fasting hypertriglyceridemia have been associated with atherosclerosis, and coronary heart disease events, even in the absence of hypercholesterolemia. Severe hypertriglyceridemia (>2000 mg/dl) can also lead to acute hemorrhagic pancreatitis.

Currently, patients having very High TG are treated with Fibric acids (gemfibrozil, Tricor, Antara), and if hyperinsulinemic, with Glucophage. Lovaza (4g/day) has been shown to be effective and safe in lowering TG levels. There is no published data which indicates that Lovaza 8 or 12 g per day would have therapeutic effectiveness in further normalizing triglycerides in subjects on maximized triglyceride lowering and Lovaza 4 g per day. We hypothesize, based on our clinical experience that increasing Lovaza to 8 and then (if necessary) to 12 g/day would safely optimize triglycerides in subjects with primary hypertriglyceridemia who failed to normalize their triglycerides on optimal therapy including Lovaza 4 g/day. ;

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Hypertriglyceridemia

Clinical Trial Details

NCT number	NCT00934219
Study type	Interventional
Source	Jewish Hospital, Cincinnati, Ohio
Contact	LUANN SIEVE
Phone	(513)585-7951
Email	luann.sieve@healthall.com
Status	Recruiting
Phase	Phase 4
Start date	July 2009
Completion date	December 2012

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03929198` - Translation of Pritikin Program to the Community	N/A
Completed	`NCT02250105` - Trial of ARI-3037MO to Reduce Triglyceride Levels in Adults With Severe (≥500 mg/dl) Hypertriglyceridemia	Phase 2
Completed	`NCT02859129` - Study to Evaluate the 2-Way Interaction Between Multiple Doses of Epanova™ and a Single Dose of Rosuvastatin (Crestor®)	Phase 1
Completed	`NCT01437930` - Intervention With n-3 Polyunsaturated Fatty Acids (PUFA)-Supplemented Products in Moderate Hypertriglyceridemic Patients	N/A
Completed	`NCT01455844` - TRIal For Efficacy of Capre on hyperTriglyceridemiA	Phase 2
Completed	`NCT01010399` - Boosted Lexiva With Lovaza Adjunctive Therapy in Hypertriglyceridemic, HIV-Infected Subjects	Phase 4
Completed	`NCT00959842` - Effects of Lovaza on Lipoprotein Composition and Function in Mild Hypertriglyceridemia	Phase 1/Phase 2
Completed	`NCT00519714` - A Study to Evaluate the Lipid Regulating Effects of 1-Methylnicotinamide (1-MNA)	Phase 2/Phase 3
Recruiting	`NCT00186537` - Comparing Tricor, Avandia, or Weight Loss to Lower Cardiovascular Risk Factors in People With High Triglycerides.	N/A
Completed	`NCT00246402` - Acipimox to Improve Hyperlipidemia and Insulin Sensitivity Associated With HIV	N/A
Completed	`NCT06020950` - Chia Seeds Consumption in Hypertriglyceridemia	N/A
Completed	`NCT02354976` - A Double-blind Randomized Placebo-controlled Study Comparing Epanova and Fenofibrate on Liver Fat in Overweight Subjects.	Phase 2
Completed	`NCT04966494` - Impact of Beans and Oats Snack Bar on Hypertriglyceridemic Women	N/A
Completed	`NCT04630366` - A Phase 1, First Time in Humans Study of NST-1024	Phase 1
Completed	`NCT04650152` - Study to Assess Tricor Therapy Effectiveness in Patients With Metabolic Syndrome (TRISTAN)
Completed	`NCT03693131` - Efficacy of MND-2119 in Participants With Hypertriglyceridemia	Phase 3
Completed	`NCT02868177` - Effect of Totum-63, Active Ingredient of Valedia, on Glucose and Lipid Homeostasis on Subjects With Prediabetes	Phase 2/Phase 3
Completed	`NCT04756180` - An Efficacy and Safety Study of Omega-3-acid Ethyl Ester in Chinese Subjects With Hypertriglyceridemia.	Phase 3
Completed	`NCT01968720` - Pilot Study To Assess CAT-2003 in Patients With Severe Hypertriglyceridemia	Phase 2
Completed	`NCT01462877` - A Study to Evaluate Fenofibrate Combination With Statin in Chinese Patients With Dyslipidemic	Phase 4

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Triglyceride Lowering Study — TGLL

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms